

# SECURITIES AND EXCHANGE COMMISSION

## FORM 8-K

Current report filing

Filing Date: **2008-08-29** | Period of Report: **2008-08-28**  
SEC Accession No. **0001193125-08-187490**

([HTML Version](#) on [secdatabase.com](http://secdatabase.com))

### FILER

#### ZYMOGENETICS INC

CIK: **1129425** | IRS No.: **911144498** | State of Incorporation: **WA** | Fiscal Year End: **1231**  
Type: **8-K** | Act: **34** | File No.: **000-33489** | Film No.: **081048031**  
SIC: **2836** Biological products, (no diagnostic substances)

Mailing Address  
1201 EASTLAKE AVENUE E  
SEATTLE WA 98102

Business Address  
1201 EASTLAKE AVENUE E  
SEATTLE WA 98102  
206-442-6600

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**Form 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

August 28, 2008

Date of Report

(Date of earliest event reported)

**ZYMOGENETICS, INC.**

(Exact Name of Registrant as Specified in Charter)

**Washington**  
(State or Other Jurisdiction  
of Incorporation)

**000-33489**  
(Commission File No.)

**91-1144498**  
(IRS Employer  
Identification No.)

**1201 Eastlake Avenue East, Seattle, Washington 98102-3702**

(Address of Principal Executive Offices, including Zip Code)

**(206) 442-6600**

(Registrant's Telephone Number, Including Area Code)

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**Item 7.01. Regulation FD Disclosure.**

On August 28, 2008, ZymoGenetics, Inc. completed the sale of a parcel of land adjacent to its headquarters in Seattle, Washington. The land was originally purchased in 2001 and 2002 for potential future expansion. ZymoGenetics received net proceeds of \$11.5 million and will record a gain on the sale of approximately \$7.0 million.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ZYMOGENETICS, INC.**

Dated: August 29, 2008

By /s/ James A. Johnson

James A. Johnson  
Executive Vice President,  
Chief Financial Officer